Ja, Nanos presentasjon på EHA ser ut til å være mer vesentlig enn det jeg først antok.
Mye å lære!
3 Likes
Hei!
Hvis du er redd for en alvorlig markedskorreksjon har jeg gode nyheter. Pharma er den bransjen som påvirkes minst. Basta!
Rett og slett fordi det ikke er nedgang i etterspørsel etter medisiner i krisetider. Det er det siste folk vil kutte ut…bokstavlig talt 
Dette kan underbygges med historiske børskurser (BP) under finanskrisen.
Dessuten er det ingen grunn til å sitte urolig i et selskap med Fast Track. Om du ikke er kjent med teknologien til Nano kan jo historisk suksessrate til selskaper med Fast Track berolige deg.
Om du setter deg inn i teknologien vil du bli enda mer beroliget. Spesielt med tanke på at FDA nå har begynt å vektlegge QoL i mye større grad. Ingen annet medisin (muligens også uavhengig av krefttype) er i nærheten av Betalutin på dette området.
I Nano nå bør brøk grådighet/ frykt være 7/1.
I mine øyne er Nano det sikreste papiret å sitte i på OSE de neste 2 årene. Kurser under 100 må sees på som en gave på dette tidspunktet.
Konklusjon:
Man selger ikke Nano-aksjer, man kjøper.
17 Likes
Interessant om de vektlegger livskvalitet mer nå en før når vurdering om godkjennelse skal gies.
Hvor finnes denne informasjonen?
Kan f.eks følge Scott gottlieb og fdaoncology på twitter
1 Like
Nordic Nanovector Announces First Patient Dosed in Pivotal PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma Patients
Oslo, Norway, 21 June 2018
Nordic Nanovector ASA (OSE: NANO) announces that the first patient has been dosed in its pivotal PARADIGME Phase 2b trial with Betalutin® (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients who are refractory to anti-CD20 immunotherapy (including rituximab), a population with high unmet medical need.
PARADIGME is a global randomised Phase 2b clinical trial comparing two Betalutin® dosing regimens (15MBq/kg Betalutin® following 40mg lilotomab pre-dosing; 20MBq/kg Betalutin® following 100mg/m2 lilotomab pre-dosing) in 3L FL patients. PARADIGME aims to enrol 130 patients across 80-85 sites in approximately 20 countries.
The objective of PARADIGME is to determine the best dosing regimen for Betalutin® as a new treatment option for 3L FL patients. The data from this study are expected to support market authorisation applications for Betalutin® as a new treatment option for 3L FL patients.
The primary endpoint for the trial is overall response rate (ORR) and secondary endpoints include duration of response (DoR), progression free survival (PFS), overall survival (OS), safety and quality of life. Initial efficacy and safety data read-out for PARADIGME is target for the first half 2020.
Lisa Rojkjaer MD, Nordic Nanovector CMO, commented: “Dosing of the first patient in PARADIGME marks important progress for Nordic Nanovector in the development of Betalutin® for the treatment of FL patients. We remain convinced of the drug’s potential in this indication following promising clinical data to-date and look forward to advancing this clinical trial to a successful conclusion.”
-End-
For further information, please contact:
IR enquiries Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedewerogerson.com
About Betalutin®
Betalutin® is a tumour-seeking anti-CD37 antibody (lilotumab) conjugated to a low-intensity radionuclide (lutetium-177). CD37 is highly expressed in B-cell non-Hodgkin’s lymphoma (NHL), representing a novel therapeutic target. Betalutin® is internalised in tumour cells and prolonged exposure of the nucleus to radiation destroys DNA leading to tumour cell death. Betalutin® also has a crossfire effect limited to a radius of 40 cells, which destroys surrounding tumour cells.
Betalutin has shown promising efficacy and tolerability in the Phase 1/2a LYMRIT 37-01 clinical study in relapsed/refractory follicular lymphoma (R/R FL) and is currently in a pivotal Phase 2b trial, PARADIGME, in third line (3L) FL patients who are refractory to standard-of-care anti-CD20-based therapy (including rituximab).
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
Further information about the Company can be found at www.nordicnanovector.com
Nyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180621.Cision.20180619:BIT:8730:0
3 Likes
Nordic Nanovector Announces First Patient Dosed in Pivotal PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma Patient
Oslo, Norway, 21 June 2018
Nordic Nanovector ASA (OSE: NANO) announces that the first patient has been
dosed in its pivotal PARADIGME Phase 2b trial with Betalutin® (177Lu
-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients
who are refractory to anti-CD20 immunotherapy (including rituximab), a
population with high unmet medical need.PARADIGME is a global randomised Phase 2b clinical trial comparing two
Betalutin® dosing regimens (15MBq/kg Betalutin® following 40mg lilotomab pre
-dosing; 20MBq/kg Betalutin® following 100mg/m2 lilotomab pre-dosing) in 3L FL
patients. PARADIGME aims to enrol 130 patients across 80-85 sites in
approximately 20 countries.The objective of PARADIGME is to determine the best dosing regimen for
Betalutin® as a new treatment option for 3L FL patients. The data from this
study are expected to support market authorisation applications for Betalutin®
as a new treatment option for 3L FL patients.The primary endpoint for the trial is overall response rate (ORR) and secondary
endpoints include duration of response (DoR), progression free survival (PFS),
overall survival (OS), safety and quality of life. Initial efficacy and safety
data read-out for PARADIGME is target for the first half 2020.Lisa Rojkjaer MD, Nordic Nanovector CMO, commented: “Dosing of the first patient
in PARADIGME marks important progress for Nordic Nanovector in the development
of Betalutin® for the treatment of FL patients. We remain convinced of the
drug’s potential in this indication following promising clinical data to-date
and look forward to advancing this clinical trial to a successful conclusion.”-End-
For further information, please contact:
IR enquiries Malene Brondberg, VP Investor Relations and Corporate
CommunicationsCell: +44 7561 431 762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedewerogerson.com
About Betalutin®
Betalutin® is a tumour-seeking anti-CD37 antibody (lilotumab) conjugated to a
low-intensity radionuclide (lutetium-177). CD37 is highly expressed in B-cell
non-Hodgkin’s lymphoma (NHL), representing a novel therapeutic target.
Betalutin® is internalised in tumour cells and prolonged exposure of the nucleus
to radiation destroys DNA leading to tumour cell death. Betalutin® also has a
crossfire effect limited to a radius of 40 cells, which destroys surrounding
tumour cells.Betalutin has shown promising efficacy and tolerability in the Phase 1/2a LYMRIT
37-01 clinical study in relapsed/refractory follicular lymphoma (R/R FL) and is
currently in a pivotal Phase 2b trial, PARADIGME, in third line (3L) FL patients
who are refractory to standard-of-care anti-CD20-based therapy (including
rituximab).About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting antibody-radionuclide-conjugate designed to advance the treatment of
non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet
medical need, representing a growing market forecast to be worth nearly USD 20
billion by 2024. Nordic Nanovector intends to retain marketing rights and to
actively participate in the commercialisation of Betalutin® in core markets.Further information about the Company can be found at www.nordicna
Ekstern link: http://www.newsweb.no/index.jsp?messageId=454290
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180621.OBI.20180621S84
20 Likes
Da var vi igang 
må bare smelle til med ny sjef og så snakker vi
7 Likes
FPD check 
️
Tjohei, balltre og tenna i medisinskapet.
Nano leverer!
Nordic Nanovector Announces First Patient Dosed in Pivotal PARADIGME Trial of Betalutin? in Third-line Follicular…
14 Likes
Og selskapet bare fortsetter å levere ihht. egen guding. Vakkert!
4 Likes
Så utrolig deilig.
Nå kan markedet få tilbake tilliten til guidingen
Gratulerer alle!
Vi er nå inne i siste fase, offisielt. Investorer med lavere risikoprofil vil komme på banen.
Svar til spm om QoL lengre opp.
Det opereres nå med Primary og Sekundære Outcome.
ORR er primærmålestokken. Men det ser ut som FDA legger mer vekt på en totalvurdering nå enn tidligere. Da kommer blandt annet DOR og QoL inn i bildet.
Bye bye 60 goodbye
Er så deilig assa. Mulig jeg selger noen av aksjene jeg kjøpte på 40-tallet på 120 kroner i morgen…
Der satt den ja! Slutter vi over 70 imorgen?
Har hørt den før…opphøyd i 12.
70 kanskje?
Trenger NANO ny CEO hvis de blir kjøpt opp innen en viss framtid ?
Maner til edruelighet, langt ifra sikkert at dette er nok til å ta oss over 65-68.
8 Likes
70 kroner? haha, Hvem er det som selger på under 100 kroner nå? Blir jo helt meningsløst. Selskapet er verdt 500 minimum ved suksess og 78% av fast-track blir suksess…De fleste klarer det regnestykket. 70 kroner er en vits nå.
2 Likes